Senior Vice President, Investor Relations
Amy Raskopf has more than 24 years of experience planning and executing investor relations (IR) programs for public and private companies, predominantly working with companies in the healthcare sector whose products have the potential to significantly improve patients’ lives.
Ms. Raskopf joined Evofem in February 2018, shortly after the Company’s transition to the public market and ahead of its first public equity raise. She has worked with the Evofem team to successfully navigate disclosure of statistically significant clinical trial data, the FDA-approval and launch of Phexxi for hormone-free, on-demand contraception, multiple fundraising rounds, and a myriad of other corporate advancements. Since December 2022 she also serves as interim head of business development, focused on partnership and licensing opportunities for Phexxi® (lactic acid, citric acid and potassium bitartrate) in foreign markets.
Prior to joining Evofem, Ms. Raskopf was Director of Corporate Communications and IR for women’s health therapeutics company Juniper Pharmaceuticals (f/k/a Columbia Laboratories) where during her 14 year tenure she led communications surrounding and was the company’s key spokesperson regarding clinical trial results, product licensing, an FDA AdComm meeting, corporate re-branding, M&A and more. She previously held a senior consulting role at In-Site Communications, a healthcare-focused investor relations firm. She began her career at Ogilvy Public Relations Worldwide, working with cross-functional teams in the investor relations and healthcare communications divisions.
Ms. Raskopf holds a Bachelor of Arts from Smith College and a Master of Fine Arts from Southern Methodist University.